Herlev and Gentofte Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2017
NCT03151343
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Herlev/Gentofte | Herlev Gentofte Hospital, Department of Neurology | Herlev & Gentofte Hospitalers Forskningsenhed

Active Ingredients

Drugs in Phase 3 Trials (1)

empagliflozin (jardiance) (1 trial)

Drugs in Phase 2 Trials (1)

tadalafil (cialis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2